Cellectis Shares: Monthly Update on Capital and Voting Rights
Understanding Cellectis’ Share Capital and Voting Rights
Cellectis is a pioneering company working in the realm of gene editing technology, and it's crucial for investors to stay informed about the current capital structure and voting rights associated with the company's shares. As of the latest update, the listing market remains Euronext Growth, reinforcing Cellectis's commitments to its stakeholders and investors.
Latest Monthly Update
The most recent update on Cellectis' share capital was reported at the end of April 2025. The total number of shares of the company now stands impressively at 100,290,220. This figure reflects the company's significant growth and ongoing strategies to enhance shareholder value.
Voting Rights Overview
Alongside the total number of shares, it is equally important to consider the voting rights attached to each share. Currently, Cellectis has a total of 89,075,490 voting rights available. These voting rights empower shareholders to participate in significant corporate decisions, shaping the future direction of the company.
Contact Information for Stakeholders
Cellectis values communication with its investors and the media. For additional inquiries or requests for information, stakeholders can reach out to the designated contacts within the organization.
Media Relations
Pascalyne Wilson, who serves as the Director of Communications, is available for media inquiries at +33 (0)7 76 99 14 33. For questions related to media or other communications, you can contact her via email at media@cellectis.com.
Investor Relations
The company encourages investors to reach out to Arthur Stril, the Chief Financial Officer and Chief Business Officer. He can be reached for any investor-related inquiries via email at investors@cellectis.com.
Conclusion
Cellectis continues to build a strong foundation with its current capital structure, reflecting the company’s commitment to its growth and shareholder engagement. Staying abreast of these updates is essential for investors eager to understand the dynamics of their investments and the future trajectory of the company.
Frequently Asked Questions
What is Cellectis known for?
Cellectis specializes in gene editing technologies and is focused on developing innovative therapies.
What is the significance of voting rights for shareholders?
Voting rights allow shareholders to influence decisions regarding company policies, leadership, and significant corporate actions.
How can investors contact Cellectis?
Investors can reach out to Cellectis through their investor relations contact, Arthur Stril, at investors@cellectis.com.
What is the current total number of shares for Cellectis?
As of April 2025, Cellectis has a total of 100,290,220 shares in its capital.
Where is Cellectis listed?
Cellectis is listed on the Euronext Growth market, among other global exchanges.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
